AUTHORS
Shuhei Asada, MD, PhD, Guangli Zhu, MD2, David M. Walter, PhD3, Yuna Hirohashi, MS4, Ramya Ravindranathan, PhD5, Lifang Sun6, Huy Nguyen7, Avneesh Saravanapavan8, Matthew L. Meyerson, MD, PhD9, Omar Abdel-Wahab, MD10, Alan D'Andrea, MD11
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Mutations in the RNA splicing factor U2AF1 are frequently detected in patients with myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (AML). Although recent studies suggest that leukemia cells harboring U2AF1 S34 mutations are sensitive to genotoxic stress, including PARP and ATR inhibition, the precise mechanism for this association remains unclear. It has recently been reported that loss of microhomology-mediated end joining (MMEJ), one of the major DNA double-strand break repair pathways, sensitizes cells to PARP and ATR inhibitors (Abeykoon and Asada et al. J Clin Invest. 135: e193006, 2025). Moreover, specific tumor subsets with intrinsic MMEJ deficiency have been identified (Asada et al. Mol Cell 84: 1–18, 2026 and Zhu and Asada et al. Sci Adv 2026, in press). We therefore hypothesized that U2AF1 S34 mutations impair MMEJ and create a therapeutically actionable dependence on compensatory DNA repair pathways.
Interestingly, we now show that the U2AF1 S34 mutation can cause exon skipping of the POLQ mRNA, POLQ protein loss, and functional MMEJ deficiency in leukemia models and patient samples. Using a dCasRx-based screen with an sgRNA library, we identified a “CAG”-containing motif, the known preferred binding site of the U2AF1 S34 mutant protein, within exon 7 of the POLQ pre-mRNA. A minigene reporter assay and systematic mutagenesis confirmed that the CAG-containing motif is required for the U2AF1 S34 mutant–driven POLQ exon 7 skipping, as disruption of this motif restored exon 7 inclusion. Using the CARPID (CRISPR-assisted RNA–protein interaction detection) system, in cells carrying endogenously tagged wild-type or S34F-mutant U2AF1, we demonstrated that U2AF1 S34F, but not wild-type U2AF1, directly binds to this “CAG”-containing motif of POLQ pre-mRNA. These data demonstrate that the mutant U2AF1 splicing factor aberrantly engages a functional exonic element in POLQ exon 7, causing exon skipping and MMEJ deficiency. Consistent with this conclusion, U2AF1 S34F-expressing leukemia cells exhibit higher formation of single-stranded DNA gaps at progressing replication forks, consistent with a POLQ low expression and an MMEJ defective phenotype.
Next, we investigated whether this MMEJ defect in leukemic cells can create a therapeutically- exploitable dependencies in the U2AF1 S34-mutant cells. We used isogenic wild-type and U2AF1 S34F-knock-in K562 cells. Genetic disruption of genes in the Fanconi anemia (FA) pathway or in the homologous recombination (HR) pathway, by CRISPR-Cas9, preferentially impaired the fitness of U2AF1 S34F-expressing cells, consistent with the known synthetic-lethal interaction between MMEJ deficiency and FA/HR pathway disruption. Consistent with compensatory FA/HR dependence, U2AF1 S34F cells were preferentially sensitive to CDK12 inhibition and RBM39 degradation. To identify strategies that enhance the therapeutic efficacy of CDK12 inhibition, we evaluated and validated candidate synthetic-lethal genes identified in a previously published THZ531-based CRISPR screen. Among these candidates, TAOK1 was recently identified as a positive regulator of HR that promotes RAD51 filament formation through USP7 phosphorylation. Intriguingly, combined TAOK1 and CDK12 inhibition markedly reduced HR activity, as measured by the DR-GFP reporter and RAD51 foci formation, and synergistically impaired the survival of U2AF1 S34F-expressing leukemia cells (Bliss synergy score, 20.624), which was accompanied by substantial accumulation of single-stranded DNA gaps and concomitantly increased double-strand breaks. This synergy was independently reproduced in other engineered U2AF1 S34F-expressing leukemia cells, including THP-1 and HL-60.
Collectively, functional RNA mapping and endogenous interaction studies reveal how U2AF1 S34F drives POLQ mis-splicing and MMEJ deficiency. Combined TAOK1 and CDK12 inhibition exploits the resulting HR dependency, inducing ssDNA gap accumulation and synergistically impairing U2AF1 S34-mutant leukemia cell survival.
DISCLOSURES
Shuhei Asada, MD, PhD: No relevant conflicts of interest to declare.